- Title
- 2 A deep intronic variant in *MME* causes autosomal recessive Charcot-Marie-Tooth neuropathy
- 3 through aberrant splicing.
- 4 Authors
- 5 Bianca R Grosz<sup>1,2</sup>, Jevin M Parmar<sup>3,4</sup>, Melina Ellis<sup>1,2</sup>, Samantha Bryen<sup>5,6</sup>, Cas Simons<sup>5,6</sup>,
- 6 Andre L.M. Reis<sup>5,7,8</sup>, Igor Stevanovski<sup>5,7</sup>, Ira W. Deveson<sup>5,7,8</sup>, Garth Nicholson<sup>2,11</sup>, Nigel
- 7 Laing<sup>3</sup>, Mathew Wallis<sup>9,10</sup>, Gianina Ravenscroft<sup>3</sup>, Kishore R. Kumar<sup>2,11,12,13</sup>, Steve Vucic<sup>2,14</sup>,
- 8 Marina L Kennerson<sup>1,2,11</sup>
- 9 ORCID:
- 10 Bianca R Grosz: 0000-0002-6926-0551
- 11 Jevin Parmar: 0000-0003-1864-8094
- 12 Melina Ellis: 0000-0002-8542-048X
- 13 Samantha Bryen: 0000-0002-4140-8622
- 14 Cas Simons: 0000-0003-3147-8042
- 15 Andre L.M Reis: 0000-0002-7300-1157
- 16 Igor Stevanovski: 0000-0002-7713-1979
- 17 Ira W Deveson: 0000-0003-3861-0472
- 18 Mathew Wallis: 0000-0002-5441-1732
- 19 Garth A Nicholson: 0000-0001-9694-066X
- 20 Nigel Laing: 0000-0001-5111-3732

- 21 Gianina Ravenscroft: 0000-0003-3634-211X
- 22 Kishore R Kumar: 0000-0003-3482-6962
- 23 Marina L Kennerson: 0000-0003-3332-5074
- 25 Affiliations:

40

50

51

54

55

- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW 2139,
   Australia
- 28 2. The University of Sydney, Camperdown, NSW, 2050, Australia
- Rare Disease Genetics and Functional Genomics Research Group, Harry Perkins
   Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia,
   6009, Australia
- Centre for Medical Research, Faculty of Health and Medical Sciences, The University
   of Western Australia, Perth, WA 6009, Australia
- Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW
   Sydney, Sydney, NSW, Australia
- Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne,
   VIC, Australia
- Genomics and Inherited Disease Program, Garvan Institute of Medical Research,
   Sydney, NSW, Australia.
  - 8. Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
- Tasmanian Clinical Genetics Service, Tasmanian Health Service, Hobart, TAS,
   Australia.
- 10. School of Medicine and Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
- 11. Molecular Medicine Laboratory and Neurology Department, Concord Repatriation
   General Hospital, Hospital Rd, Concord, NSW, 2139, Australia
- 12. Translational Neurogenomics Group, Genomic and Inherited Disease Program, The
   Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010,
   Australia
  - 13. St Vincent's Healthcare Campus, Faculty of Medicine, UNSW Sydney, Level 5, De Lacy Building, St Vincent's Hospital, Darlinghurst, NSW, 2010, Australia.
- 14. Brain and Nerve Research Centre, The University of Sydney, NSW 2139,
   Australia

Abstract

57 58

59

61

62

63

64

68

70

76

77

78

79

80

**Background:** Loss-of-function variants in MME (membrane metalloendopeptidase) are a

known cause of recessive Charcot-Marie-Tooth Neuropathy (CMT). A deep intronic variant,

60 MME c.1188+428A>G (NM\_000902.5), was identified through whole genome sequencing

(WGS) of two Australian families with recessive inheritance of axonal CMT using the seqr

platform. MME c.1188+428A>G was detected in a homozygous state in Family 1, and in a

compound heterozygous state with a known pathogenic MME variant (c.467del;

p.Pro156Leufs\*14) in Family 2.

65 **Aims:** We aimed to determine the pathogenicity of the MME c.1188+428A>G variant

66 through segregation and splicing analysis.

67 **Methods:** The splicing impact of the deep intronic *MME* variant c.1188+428A>G was

assessed using an *in vitro* exon-trapping assay.

69 **Results:** The exon-trapping assay demonstrated that the MME c.1188+428A>G variant

created a novel splice donor site resulting in the inclusion of an 83 bp pseudoexon between

71 MME exons 12 and 13. The incorporation of the pseudoexon into MME transcript is predicted

72 to lead to a coding frameshift and premature termination codon (PTC) in MME exon 14

73 (p.Ala397ProfsTer47). This PTC is likely to result in nonsense mediated decay (NMD) of

74 *MME* transcript leading to a pathogenic loss-of-function.

75 **Interpretation:** To our knowledge, this is the first report of a pathogenic deep intronic *MME* 

variant causing CMT. This is of significance as deep intronic variants are missed using whole

exome sequencing screening methods. Individuals with CMT should be reassessed for deep

intronic variants, with splicing impacts being considered in relation to the potential

pathogenicity of variants.

Key Words (up to 5): Charcot-Marie-Tooth disease, splicing, MME, recessive, deep intronic

### Introduction

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

Charcot-Marie-Tooth neuropathy (CMT) is the most common inherited peripheral neuropathy, affecting 1/2500 individuals<sup>1</sup>. CMT is characterized by progressive lengthdependent loss of peripheral motor and sensory nerves, resulting in distal muscle weakness and sensory symptoms<sup>2</sup>. Patients are broadly divided into subtypes based on whether nerve conduction studies (NCS) indicating demyelinating (CMT1) or axonal (CMT2) forms of the disease. Recessive loss-of-function variants in the membrane metalloendopeptidase (MME) gene have been previously reported to cause axonal Charcot-Marie-Tooth neuropathy type 2T (CMT2T; OMIM: #617017)<sup>3-11</sup>. MME encodes for neprilysin, a widely expressed membranebound metallopeptidase that has a key role in neuropeptide processing <sup>12</sup>. A significant portion of patients with axonal CMT remain genetically undiagnosed<sup>13–17</sup>, indicating that further disease-causing genes and pathogenic variants in known genes are yet to be identified. Splicing variants are increasingly being recognized as a cause of Mendelian disease 18,19. The precise removal of introns (non-coding regions) and inclusion of exons (coding regions) in the final mature mRNA relies on the spliceosome and auxiliary splicing factors recognizing specific sequence motifs, such as the 5' donor splice site and 3' acceptor splice site. Splicealtering variants can weaken or abolish recognition of the correct splice sites, or alternatively strengthen or create cryptic splice sites that mimic consensus splicing sequences<sup>20</sup>. These variants typically lead to one or more mis-splicing events that result in the skipping of partial or complete exons, and/or the retention of partial or complete introns <sup>21–42</sup>. Pathogenic splicing variants have been found in several CMT genes including  $MPZ^{21,30,39,40}$ , MFN2<sup>22,30,31</sup>, LRSAM1<sup>23</sup>, IGHMBP2<sup>24</sup>, INF2<sup>25</sup>, MCM3AP<sup>26</sup>, SH3TC2<sup>30,32,38</sup>, GDAP1<sup>27,42</sup>, SBF1<sup>28</sup>, NDRG1<sup>37</sup>, and FGD4<sup>29</sup>. Variants affecting canonical splice donor and acceptor sites have also been described in  $MME^{4,41}$ .

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

Exon-trapping, also known as a mini-gene assay, is an in vitro technique used to identify exons in a genomic region of interest<sup>43</sup>. This is of particular use when relevant patient tissue is unavailable or when relevant transcripts may be unstable or degraded by nonsense mediated decay (NMD) 44. The genomic region of interest is cloned into an exon-trapping vector between two known exons. This exon-trapping vector is transfected into a cell line where it is transcribed and undergoes a series of post-transcriptional processes that include pre-mRNA splicing to create mature mRNA. This mRNA consists of the 'trapped' exons of the genomic region of interest flanked by the known exons, which can then be Sanger sequenced to characterize the 'trapped' exons, Comparison of 'trapped' exons between wild type and variant genomic sequences can also indicate if a candidate variant affects splicing 45-<sup>51</sup>. The well-validated exon-trapping vector pSpliceExpress <sup>52</sup> consists of known exons of the rat insulin gene, Ins2, and has been used previously to determine the splicing impacts of multiple pathogenic variants in Mendelian disease 45-51. Here we report a deep intronic variant in MME [chr3:155142758A>G (hg38); MME c.1188+428A>G], found in a recessive state in two Australian families. Exon-trapping revealed that this variant creates a novel splice donor site in MME intron 12 (NM\_000902.5) which, along with a preceding existing cryptic splice acceptor site, results in the incorporation of an 83 bp pseudoexon in the MME transcript [chr3:155,142,675-155,142,757 (hg38); r.1188\_1189ins[1188+345\_1188+427]]. The coding frameshift caused by this pseudoexon leads to a PTC in exon 14 and likely NMD of the MME transcript (p.Ala397ProfsTer47), resulting in a loss of *MME* function.

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

Materials and Methods: Subjects Members of Family 1 were recruited and informed consent was obtained for this study using protocols approved by the Sydney Local Health District Human Ethics Research Committee (2019/ETH07839). Recruitment and informed consent for the proband of Family 2 was approved by the Human Research Ethics Committee of the Royal Melbourne Hospital (HREC/16/MH/251). Variant Detection Genomic DNA for Family 1 was extracted from peripheral blood using the PureGene Kit (Qiagen) following the manufacturer's instructions. WGS for two individuals in Family 1 (V:1 and V:3) was outsourced to the Garvan Sequencing Platform. Paired-end sequencing reads of 150 base pairs were generated using the Illumina NovaSeq 6000 sequencing machine, with 30-fold average read depth. In Family 2, genomic DNA for the proband was extracted at the Department of Diagnostic Genomics (PathWest, Perth, Australia) using the QIAsymphonySP machine and QIAsymphone® DSP DNA Midi Kit. The proband underwent WGS at the Australian Genomics Research Facility (AGRF), Melbourne, following GATK4 best-practices. Pairedend sequencing reads of 150 base pairs were generated using the Illumina NovaSeq 6000 sequencing machine, with 30-fold average read depth. Parental DNA was not available for sequencing. WGS data processing was performed at the Centre for Population Genomics (CPG) following the DRAGEN GATK best practices pipeline. Reads were aligned to the hg38 reference genome using Dragmap (v1.3.0). Cohort-wide joint calling of single nucleotide variants

(SNVs) and small insertion/deletion (indel) variants was performed using GATK

151 HaplotypeCaller (v4.2.6.1) with "--dragen-mode" enabled. Sample sex and relatedness quality checks were performed using Somalier (v0.2.15)<sup>53</sup>. Variants were annotated using 152 VEP 105, and loaded into the web-based variant filtration platform, seqr<sup>54</sup>. A WGS search 153 was conducted using the seqr<sup>45</sup> platform for low minor allele frequency (<0.01) variants in 154 155 CMT-related genes, for both Family 1 and 2 [gene list-Hereditary Neuropathy\_CMT\_IsolatedAndComplex (Version 2.14)<sup>55</sup>]. Additionally, variants were 156 **CPG** Automated 157 analyzed by the Interpretation Pipeline (AIP, 158 https://github.com/populationgenomics/automated-interpretation-pipeline). In silico splicing analysis was conducted using SpliceAI<sup>56</sup>. 159 160 Segregation Analysis 161 The MME c.1188+428A>G variant in Family 1 and Family 2 was amplified using primers 162 MME12 (5'-CTCAGCCGAACCTACAAGGA-3'; that spanned intron GCAAATGCTGCTTCCACAT-3') to produce a 1264 bp amplicon [chr3:155,142,289-163 164 155,143,552 (hg38)]. An internal sequencing primer used (5'-165 CTGTGTTAAAAGTAATTTCGGGG-3') and the amplicon was Sanger sequenced. The MME c.467del variant in Family 2 was amplified (5'-GCAGAGCCGTATGCATCACT-3'; 166 167 5'-TTCAGCTGTCCAAGAAGCACC-3'). 717bp amplicon produced was [chr3:155,116,171-155,116,887 (hg38)], which was subsequently Sanger sequenced. 168 169 Sanger Sequencing 170 For Family 1, PCR amplicons were sent to Garvan Molecular Genetics, Garvan Institute 171 172 (Sydney, Australia) for Sanger sequencing using BigDye Terminator cycle sequencing 173 protocols. For Family 2, proband PCR amplicons were Sanger sequenced at AGRF, Perth 174 using BigDye Terminator sequencing protocols. Sequences were visualized and analyzed 175 using Snapgene Software version 7.1 (www.snapgene.com).

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

Oxford Nanopore Technologies (ONT) Long Read Sequencing High molecular weight (HMW) DNA samples of the Proband in Family 2 were transferred to the Garvan Sequencing Platform for targeted long-read sequencing analysis on ONT instruments. Prior to ONT library preparations, DNA was sheared to ~20-25 kb fragment size using a MegaRuptor 3 instrument and visualized post-shearing on an Agilent FemtoPulse. Sequencing libraries were prepared from ~3-5 µg of HMW DNA, using native library prep kit SQK-LSK114, according to manufacturer's instructions. Each library was loaded onto a R10.4.1 flow cell and sequenced on a PromethION device with live target selection/rejection executed by the ReadFish software package<sup>57</sup>. Detailed descriptions of software and hardware configurations used for ReadFish are provided in a previous publication<sup>58</sup>. Samples were run for a maximum duration of 72 h, with nuclease flushes and library reloading performed at approximately 24- and 48-h timepoints for targeted sequencing runs, to maximize sequencing yield. Raw ONT sequencing data was converted to BLOW5 format<sup>59</sup> using slow5tools (v.0.3.0)<sup>60</sup> then base-called using Guppy (v6). Resulting FASTQ files were aligned to the hg38 reference genome using minimap2 (v2.14-r883)<sup>61</sup>. Variants were called using clair3<sup>62</sup>, phased using Whatshap<sup>63</sup> and visualized using the Integrative Genomics Viewer (IGV,  $v2.17.3)^{64}$ . Cell Culture The human HeLa cervical epithelial cell line (ATCC) was maintained in Dulbecco's Modified Eagle's Medium (DMEM)(Gibco) containing 10% (v/v) fetal bovine serum (FBS) (Gibco), +100 U/mL penicillin (Gibco), and 100 µg/mL streptomycin (Gibco) at 37°C in humidified air and 5% CO2.

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

Cloning Procedures The region surrounding MME c.1188+428A>G [chr3:155,141,790-155,143,755 (hg38)] was amplified from the genomic DNA of a heterozygous carrier of the c.1188+428A>G variant, using attB adapter primers (5'-AAAAAGCAGGCTTCGCTCTTAAATGGTTGGCTT-3'; 5'-AGAAAGCTGGGTAACTAGACTCTTGGGGAAGGC -3'). The MME amplicon was then cloned into the exon-trapping pSpliceExpress vector between flanking Ins2 exons using a two-step Gateway cloning BP reaction (ThermoFisher). pSpliceExpress was a gift from Stefan Stamm (Addgene plasmid #32485)<sup>52</sup>. The pSpliceExpress-MME clones were then Sanger sequenced to verify the correct insertion of MME and to determine the c.1188+428A>G genotype of each clone (as the genomic DNA template was heterozygous for the variant). *In vitro* exon-trapping HeLa cells were grown to approximately 70% confluence in a 6-well plate. HeLa cells were separately transfected with either 2 µg of pSpliceExpress-MME<sub>WT</sub> or 2 µg of pSpliceExpress-MME<sub>c.1188+428A>G</sub> using Lipofectamine 3000 (ThermoFisher). RNA extraction was performed 48 h following transfection using the RNEasy Mini Kit (Qiagen), and reverse-transcribed template was prepared using the iScript cDNA Synthesis Kit (Bio-Rad). PCR amplification of cDNA was conducted using primers designed to anneal to the flanking Ins2 exons (5'-CAGCACCTTTGTGGTTCTCA-3'; 5'-CAGTGCCAAGGTCTGAAGGT-3'). The RT-PCR amplicons were size fractionated using a 1.5% w/v agarose gel. The largest amplicon for each vector was gel-purified using Isolate II PCR and Gel Kit (Bioline) for Sanger Sequencing. *In silico* splicing analysis of reported *MME* variants All reported MME variants in gnomAD v.4.0.0 were detected by searching the gnomAD browser for the genomic region corresponding with the MME gene; '3-155024124-155183704'(hg38). The MME variants reported in gnomAD were then exported using the

'Export Variants to CSV' function. The consequences of the variants were described by gnomAD using the Variant Effect Predictor (VEP) annotation based on the most deleterious predicted functional effect of each variant  $^{65}$ . These variants were then filtered for a minor allele frequency (MAF) <0.01 and a maximum SpliceAI  $\Delta$ score >0.8 (high precision splicing change prediction  $^{66}$ ) as annotated by gnomAD.

# Results:

Clinical Phenotypes

Family 1 consists of four affected siblings from a consanguineous family of European (non-Finnish) background (Figure 1a). The phenotype was consistent with a generalized sensorimotor axonal neuropathy and sensory ataxia without cerebellar signs (Table 1), and was confirmed with NCS for individuals V:1 and V:6 (Table 2). Affected individuals had previously undergone diagnostic and research whole exome sequencing with negative results.

Family 2 consists of one affected female born to a healthy, non-consanguineous couple (Figure 1b). Neurological examination revealed mild distal upper limb weakness and moderate distal lower limb weakness (Table 1). NCS showed evidence of an axonal sensorimotor neuropathy (Table 2). Bilateral MRI of the thighs and calves showed muscle atrophy (Supplementary Figure 1).

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

Genetic Analysis WGS screening using the seqr platform in Family 1 revealed a single homozygous variant in two affected individuals (V:1 and V:3), MME c.1188+428A>G (NM\_000902.5). This variant was reported in dbSNP build 155<sup>67</sup> (rs61758195), with a low MAF in gnomAD v4.0.0<sup>68</sup> (10/152120), All of Us  $(35/490,748)^{69}$ , and TOPMED<sup>70</sup> (15/264290). No homozygous individuals were reported in gnomAD, All of Us, or TOPMED. SpliceAI predicted that MME c.1188+428A>G could create a strong novel splice donor site (Score 0.97; where a SpliceAI score above 0.8 is considered a 'high precision' predicted splice variant<sup>56</sup>). This in turn strengthened the SpliceAI prediction for a cryptic splice acceptor site 83 bp upstream of the novel splice donor site (Score 0.99). Segregation analysis in Family 1 confirmed the biallelic inheritance of the MME c.1188+428A>G variant segregated with the CMT phenotype (Figure 1a). sequencing of DNA from available individuals showed that all affected individuals were homozygous for the MME c.1188+428A>G variant and unaffected individuals were carriers (Supplementary Figure 2). WGS screening using the seqr platform and AIP was conducted in the proband of Family 2 (II:1). The MME c.1188+428A>G variant was detected in a compound heterozygous state with a second MME variant (MME c.467del; p.Pro156Leufs\*14), which has previously been reported as pathogenic<sup>41</sup> (Figure 1b). Sanger sequencing validated the presence of each MME variant in the index individual (Supplementary Figure 3). As parental DNA was unavailable, ONT long-read sequencing was conducted to phase the heterozygous MME variants in the proband (Figure 1c-d). ONT long-read sequencing confirmed that MME c.1188+428A>G (boxed red in Figure 1c) and c.467del (boxed red in Figure 1d) were present on alternative haplotypes (hap-1: red, hap-2: blue) and therefore were in *trans* in the proband.

### *In vitro* exon-trapping of *MME*-pSpliceExpress vectors

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

Two separate exon-trapping pSpliceExpress vectors were generated to assess the *in vitro* splicing impact of the MME c.1188+428A>G variant: pSpliceExpress-MME<sub>WT</sub> (wild-type) and pSpliceExpress-MME<sub>c.1188+428A>G</sub> (variant). A schematic of the constructs and relevant SpliceAI scores are shown in Figure 2a. RT-PCR products produced following transfection of these vectors were analyzed using gel electrophoresis (Figure 2b), which revealed a visible size difference between the wild-type (381 bp) and MME c.1188+428A>G amplicons (464 bp). The gel-purified amplicons were Sanger sequenced and the sequencing was aligned to the WT MME mRNA sequence. The sequenced products showed that the pSpliceExpress-MME<sub>WT</sub> produced a transcript that was correctly spliced between MME exon 12 and 13 (Figure 2c). In contrast, exon-trapping of the pSpliceExpress-MME<sub>c.1188+428A>G</sub> vector showed that an 83 bp pseudoexon had been spliced between MME exon 12 and 13 (Figure 2d). A BLAT search<sup>71</sup> using the sequence of the trapped pseudoexon revealed alignment to the intronic region directly upstream of the MME c.1188+428A>G variant [chr3:155,142,675-155,142,757 (hg38)]. This suggests that the MME c.1188+428A>G variant creates a novel splice donor site leading to the aberrant inclusion of 83 bp of intronic MME sequence in the final spliced transcript, as predicted by SpliceAI. Prediction of the novel MME coding sequence caused by the introduction of the pseudoexon showed that a PTC was generated in exon 14 (p.Ala397ProfsTer47) at genomic position chr3:155,144,368 (hg38)(Supplementary Figure 4). This PTC likely leads to NMD of the *MME* transcript.

#### *In silico* splicing analysis of *MME* variants

All reported *MME* variants in gnomAD v.4.0.0 were assessed using the integrated SpliceAI scores to determine if splicing variants in *MME* were a likely underrecognized cause of disease. There were 37,264 total variants reported in *MME* in gnomAD, of which 35,673 variants had a MAF <0.01. Of these, 88 variants had a maximum SpliceAI Δscore above 0.8

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

(Supplementary Table 1). There were no homozygotes reported for any of the 88 MME putative splicing variants. The majority of these predicted splicing variants were predicted to directly change either the canonical splice donor sites (26/88) or canonical splice acceptor sites (30/88) of MME, including an inframe deletion (c.1317\_1317+2del) and a frameshift variant (c.957+1del). An additional nine variants were predicted to affect a splicing region, including one which is also annotated as a synonymous variant (c.1188G>A; p.Lys396Lys). Nine missense variants (p.Asp209Gly, p.Ile217Ser, p.Glu282Val, p.Arg365Ile, p.Ser436Gly, p.Asp533Gly, p.Ile553Val, p.Val554Phe, p.Gln692Arg) and a synonymous variant (p.Gly417Gly) were also predicted to alter splicing. Twelve variants were annotated as 'intron variants', of which two could be considered 'deep intronic' (c.1188+428A>G, described in this manuscript, and c.197-9871A>G). Interestingly, further analysis using SpliceAI demonstrated that MME c.197-9871A>G was predicted to create a splice donor site (Score 0.81) and strengthen an upstream cryptic splice acceptor site (Score 0.81) in a similar manner to c.1188+428A>G, thereby possibly creating an in-frame 96 bp pseudoexon.

## Discussion

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

Here we report a deep intronic variant, MME c.1188+428A>G causing recessive CMT2T in two unrelated Australian families. This variant results in a pseudoexon that likely leads to NMD of the MME transcript, resulting in a loss-of-function. This is in keeping with previously reported MME variants which have broadly been characterised as 'loss-offunction' variants. To our knowledge, this is the first report of a pathogenic deep intronic variant in MME. Given that a significant portion of patients with axonal CMT remain genetically undiagnosed<sup>13-17</sup>, it's possible that deep intronic variants in MME explain a portion of this diagnostic gap. Individuals from Family 1 previously underwent both diagnostic WES and research WES, and the proband in Family 2 previously underwent targeted gene panel testing (PathWest neuro v3). These testing methods did not capture deep intronic regions and returned negative results. However, deep intronic regions have previously been shown to have a higher prevalence of variants than coding regions and canonical splice sites<sup>72</sup>. Our findings suggest that intronic SNPs should be analyzed to determine if they impact splicing before they are dismissed as benign. Detection and functional validation of deep intronic variants has previously been shown to increase diagnostic rates in other Mendelian diseases including Xlinked Alport syndrome<sup>73</sup>, inherited retinal disorders<sup>74,75</sup>, and dystrophinopathy<sup>76,77</sup>. Pathogenic deep intronic variants, such as described here, are likely to be underreported amongst CMT-causing genes due to a lack of detection by WES and targeted gene panels, and a lack of functional investigation upon detection. The MME c.1188+428A>G variant was reported in multiple different genetic ancestry groups in gnomAD v.4.0.068, including in the European (Non-Finnish) (8/68008), African/African

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

American (1/41432), and 'remaining' (1/2092) ancestry groups. This was also reflected in the 'All of Us' Research Program<sup>69</sup>, which reported the MME c.1188+428A>G variant in the African (2/107,888) and European populations (33/256,804). Whilst it is possible that MME c.1188+428A>G represents a recurrent de novo variant, it is also likely that this variant has persisted at low levels in the global population. As this variant is missed by WES and may not be prioritised by variant-filtering approaches focusing on coding variants, this variant may therefore represent an underappreciated cause of recessive CMT. This is further supported by its detection in two Australian CMT families who are not known to be related. Whilst the predicted splicing variants reported in MME are individually rare, we have described eighty-eight variants in gnomAD that are predicted by SpliceAI to alter splicing. Nine of these variants were annotated as missense variants, and one was a synonymous change. This is of note as these 'missense' variants are often assumed to result in a single amino acid change, and synonymous variants are often considered functionally neutral, with their effect on splicing typically not assessed<sup>78</sup>. Our results suggest that the discovery of any of these eighty-eight variants in a homozygous or compound heterozygous state in an individual with CMT should prompt further functional investigation of their effect on splicing of the *MME* transcript. Prior to functional validation, MME c.1188+428A>G was considered a variant of uncertain significance (VUS) according to American College of Medical Genetics and Genomics (ACMG) criteria<sup>79</sup> (BP4, PM2, PM3, PP1), However, the functional evidence generated by the splicing assay now allows for the addition of PVS1 (null variant in a gene where loss-offunction is a known mechanism of disease) and PS3 (well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product) criteria. This allows reclassification of the variant as 'pathogenic'. Therefore, this work demonstrates the

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

importance of functional validation to confirm the effect of candidate variants on splicing to increase diagnostic rates for those with inherited disease. Previously described homozygous MME patients typically have a phenotype consistent with late-onset axonal neuropathy. In contrast, three of the four affected siblings in Family 1 described childhood onset and the proband of Family 2 described symptom onset in early adulthood. It has also previously been reported that heterozygous MME variants can cause spinocerebellar ataxia type 43 (SCA43)<sup>80</sup> as well as autosomal dominant CMT<sup>3</sup>. However, the individuals in Family 1 who were MME c.1188+428A>G heterozygotes were all clinically assessed as neurologically normal, including an individual who is in their seventh decade. Homozygous affected individuals in Family 1 were noted to have a sensory ataxia rather than cerebellar ataxia, although MRI brain studies were not conducted. Therefore, our findings here do not support a role for MME c.1188+428A>G to cause SCA43 or autosomal dominant CMT, and further expand the phenotype of recessive CMT2T. Understanding the specific effects of splice-affecting variants is crucial for developing potential therapeutic strategies. Antisense oligonucleotides (ASOs) that modulate splicing are an active area of research, including individualized approaches to treat rare genetic diseases<sup>81–83</sup>. Several antisense nucleotides that modify splicing have been approved by the United States Food and Drug Administration and have resulted in marked improvements in clinical outcomes in those with genetic diseases<sup>84-94</sup>. An FDA-approved "n-of-1" ASO, milasen, successfully blocked pathogenic pseudoexon inclusion in MFSD8 in a patient with neuronal ceroid lipofuscinosis type 7<sup>94</sup>. ASOs which block pathogenic pseudoexons, such as that created by MME c.1188+428A>G, have also been described in in vivo preclinical models<sup>93,95–99</sup>. As such, individuals with the MME c.1188+428A>G variant may represent a

form of CMT that is treatable through personalized ASO therapy and warrants further investigation.

Acknowledgements
This work was funded by the Medical Research Future Fund (MRFF) Genomics Health
Futures Mission (APP2007681). JMP is supported by the Australian Government Research
Training Program. IWD was supported by MRF2025138 & MRF2023126. Genomic analysis
was supported by the Centre for Population Genomics (Garvan Institute of Medical Research
and Murdoch Children's Research Institute) and was funded in part by a National Health and
Medical Research Council investigator grant (2009982) and the Medical Research Future
Fund (MRFF) Genomics Health Futures Mission (2008820).

Figure Legends:

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

Figure 1: The MME c.1188+428A>G (NM\_000902.5) variant segregates with recessive **CMT in two families.** A) Family 1 pedigree showing the associated genotypes for the *MME* c.1188+428A>G (NM\_000902.5) variant. Affected individuals in the fifth generation are homozygous (G/G). Unaffected individuals in the fifth (V) and sixth (VI) generation are heterozygous (A/G). Squares represent males and circles represent females, solid symbol denotes affected individual. The double line in the fourth (IV) generation indicates a consanguineous relationship. The MME c.1188+428 genotype is denoted beneath individuals who underwent Sanger sequencing, with the pathogenic 'G' allele in red text. B) A pedigree showing the associated genotypes for MME c.1188+428A>G and MME c.467del in the index individual in Family 2. C-D) Haplotype phasing showed that the c.1188+428A>G (C) and c.467del (D) variants were present on alternative haplotypes (light red and light blue), thus inherited in trans in the proband of Family 2. Phased targeted ONT long-read sequencing reads were visualized using the Integrative Genomics Viewer (IGV; v2.17.3). Figure 2. An exon-trapping assay was used to analyze splicing changes caused by the MME c.1188+428A>G variant. A) Schematic of the pSpliceExpress-MME<sub>WT</sub> (wild-type) and pSpliceExpress-MME<sub>c.1188+428A>G</sub> (variant) constructs. Both constructs consisted of an RSV LTR promoter region (blue) controlling transcription of a minigene of MME exons 12 and 13 (grey) flanked by Ins2 exon 2 and Ins2 exon 3 (black). The constructs differed in the presence of either an A (wild type: green text) or a G allele (mutant: red text) at MME c.1188+428A>G. i) The wild type sequence was not predicted to contain any strong splice sites when assessed using SpliceAI, with a score of 0.11 for the acceptor site (purple text) and 0.00 for the donor site (green text). ii) SpliceAI predicted that the MME c.1188+428A>G variant (red arrow) would create a strong splice donor site [Score: 0.97 (Δ 0.97); red text], which then strengthened the prediction of a splice acceptor site 83 bp upstream [Score 0.99]

(Δ0.97); purple text]. The predicted 83 bp pseudoexon sequence is capitalized and boxed in red. B) The amplicon produced by the pSpliceExpress-*MME*<sub>c.1188+428A>G</sub> vector (464 bp) showed a visible increase in product size when compared to the amplicon produced by pSpliceExpress-*MME*<sub>WT</sub> (381 bp). The 158 bp RT-PCR product produced by both vectors indicated splicing and ligation of the flanking *Ins2* exon 2 and exon 3. Lanes: L: HyperLadder 100 bp (Bioline); WT: wild-type; NRTC: negative cDNA conversion control (no reverse transcriptase). NTC: negative PCR reaction control (no cDNA template). C) Sanger sequencing of the pSpliceExpress-*MME*<sub>WT</sub> RT-PCR product confirmed correct splicing between *MME* exon 12 and 13. D) Sanger sequencing of the pSpliceExpress-*MME*<sub>c.1188+428A>G</sub> RT-PCR product revealed the presence of a novel 83 bp pseudoexon (red) between *MME* exon 12 and 13. Abbreviations: RSV LTR: Rous Sarcoma Virus Long Terminal Repeat promoter; *Ins2*: rat preproinsulin 2 gene.

References

430 431

440

- Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. *Clin Genet*.
   1974;6:98-118.
- Szigeti K, Lupski JR. Charcot–Marie–Tooth disease. *European Journal of Human Genetics*. 2009;17(6):703-710. doi:10.1038/ejhg.2009.31
- Senderek J, Lassuthova P, Kabzińska D, et al. The genetic landscape of axonal neuropathies in the middle-aged and elderly. *Neurology*. 2020;95(24).
   doi:10.1212/WNL.000000000011132
- 439 4. Higuchi Y. Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth

disease type 2. Ann Neurol. 2016;79:659-672.

- 441 5. Record CJ, Pipis M, Skorupinska M, et al. Whole genome sequencing increases the diagnostic rate in Charcot-Marie-Tooth disease. *Brain*. Published online March 14,
- 443 2024. doi:10.1093/brain/awae064
- 444 6. Jamiri Z, Khosravi R, Heidari MM, Kiani E, Gharechahi J. A nonsense mutation in 445 <scp> MME </scp> gene associates with autosomal recessive late □ onset
- 445 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   446 
   447 
   448 
   449 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   440 
   <l
- doi:10.1002/mgg3.1913
- Taghizadeh S, Vazehan R, Beheshtian M, et al. Molecular Diagnosis of Hereditary
- Neuropathies by Whole Exome Sequencing and Expanding the Phenotype Spectrum.
- 450 *Arch Iran Med.* 2020;23(7):426-433. doi:10.34172/AIM.2020.39
- 451 8. Ando M, Higuchi Y, Yuan J, et al. Comprehensive Genetic Analyses of Inherited 452 Peripheral Neuropathies in Japan: Making Early Diagnosis Possible. *Biomedicines*.
- 453 2022;10(7):1546. doi:10.3390/biomedicines10071546
- 9. Megarbane A, Bizzari S, Deepthi A, et al. A 20-year Clinical and Genetic
- Neuromuscular Cohort Analysis in Lebanon: An International Effort. *J Neuromuscul*456 *Dis.* 2022;9(1):193-210. doi:10.3233/JND-210652
- 457 10. Høyer H, Hilmarsen HT, Sunder-Plassmann R, et al. A polymorphic AT-repeat causes
- frequent allele dropout for an *MME* mutational hotspot exon. *J Med Genet*.
- 459 2022;59(10):1024-1026. doi:10.1136/jmedgenet-2021-108281
- 460 11. Dupuis M, Raymackers JM, Ackermans N, Boulanger S, Verellen-Dumoulin C.
- 461 Hereditary axonal neuropathy related to MME gene mutation in a family with
- fetomaternal alloimmune glomerulonephritis. *Acta Neurol Belg.* 2020;120(1):149-154.
- doi:10.1007/s13760-020-01275-9
- 12. Krämer HH, He L, Lu B, Birklein F, Sommer C. Increased pain and neurogenic
- inflammation in mice deficient of neutral endopeptidase. *Neurobiol Dis.*
- 466 2009;35(2):177-183. doi:10.1016/j.nbd.2008.11.002

- 467 13. Gemelli C, Geroldi A, Massucco S, et al. Genetic Workup for Charcot-Marie-Tooth
- Neuropathy: A Retrospective Single-Site Experience Covering 15 Years. *Life (Basel)*.
- 469 2022;12(3). doi:10.3390/life12030402
- 470 14. Candayan A, Parman Y, Battaloğlu E. Clinical and Genetic Survey for Charcot-Marie-
- 471 Tooth Neuropathy Based on the Findings in Turkey, a Country with a High Rate of
- 472 Consanguineous Marriages. *Balkan Med J.* 2022;39(1):3.
- 473 doi:10.4274/BALKANMEDJ.GALENOS.2021.2021-11-13
- 474 15. Rudnik-Schöneborn S, Tölle D, Senderek J, et al. Diagnostic algorithms in Charcot-
- Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis
- of 1206 index patients. Clin Genet. 2016;89(1):34-43. doi:10.1111/cge.12594
- 477 16. Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients
- enrolled in the Inherited Neuropathies Consortium natural history study: a cross-
- 479 sectional analysis. 2015;86(8):873-878. doi:10.1136/jnnp-2014-308826
- 480 17. Ma Y, Duan X, Liu X, Fan D. Clinical and mutational spectrum of paediatric Charcot-
- 481 Marie-Tooth disease in a large cohort of Chinese patients. *Front Genet*. 2023;14.
- 482 doi:10.3389/fgene.2023.1188361
- 483 18. Lord J, Baralle D. Splicing in the Diagnosis of Rare Disease: Advances and
- 484 Challenges. Front Genet. 2021;12:689892. doi:10.3389/fgene.2021.689892
- 485 19. Wang R, Helbig I, Edmondson AC, Lin L, Xing Y. Splicing defects in rare diseases:
- transcriptomics and machine learning strategies towards genetic diagnosis. *Brief*
- 487 *Bioinform*. 2023;24(5). doi:10.1093/bib/bbad284
- 488 20. Anna A, Monika G. Splicing Mutations in Human Genetic Disorders: Examples,
- 489 Detection, and Confirmation. Vol 59. Springer Verlag; 2018:253-268.
- 490 doi:10.1007/s13353-018-0444-7
- 491 21. Corrado L, Magri S, Bagarotti A, et al. A novel synonymous mutation in the MPZ
- 492 gene causing an aberrant splicing pattern and Charcot-Marie-Tooth disease type 1b.
- 493 Neuromuscular Disorders. 2016;26(8):516-520. doi:10.1016/j.nmd.2016.05.011
- 494 22. Boaretto F, Vettori A, Casarin A, et al. Severe CMT type 2 with fatal encephalopathy
- associated with a novel MFN2 splicing mutation. *Neurology*. 2010;74(23).
- 496 doi:10.1212/WNL.0b013e3181e240f9
- 497 23. Engeholm M, Sekler J, Schöndorf DC, et al. A novel mutation in LRSAM1 causes
- 498 axonal Charcot-Marie-Tooth disease with dominant inheritance. *BMC Neurol*.
- 499 2014;14(1):118. doi:10.1186/1471-2377-14-118
- 500 24. Cassini TA, Duncan L, Rives LC, et al. Whole genome sequencing reveals novel
- 501 *IGHMBP2* variant leading to unique cryptic splice □ site and Charcot □ Marie □ Tooth
- phenotype with early onset symptoms. *Mol Genet Genomic Med*. 2019;7(6):e00676.
- 503 doi:10.1002/mgg3.676
- 504 25. Echaniz Laguna A, Latour P, Echaniz-Laguna A, Latour P, Echaniz Laguna A,
- Latour P. A cryptic splicing mutation in the INF2 gene causing Charcot-Marie-Tooth

- disease with minimal glomerular dysfunction. *Journal of the Peripheral Nervous*System. 2019;24(1):120-124. doi:10.1111/jns.12308
- Ylikallio E, Woldegebriel R, Tumiati M, et al. MCM3AP in recessive Charcot-Marie Tooth neuropathy and mild intellectual disability. *Brain*. 2017;140(8):2093-2103.
   doi:10.1093/brain/awx138
- Numakura C, Lin C, Ikegami T, Guldberg P, Hayasaka K. Molecular analysis in Japanese patients with Charcot-Marie-Tooth disease: DGGE analysis for PMP22,
- 513 MPZ, and Cx32/GJB1 mutations. *Hum Mutat*. 2002;20(5):392-398.
- doi:10.1002/humu.10134
- 515 28. Flusser H, Halperin D, Kadir R, Shorer Z, Shelef I, Birk OS. Novel SBF1 splice-site
- null mutation broadens the clinical spectrum of Charcot-Marie-Tooth type 4B3
- 517 disease. Clin Genet. 2018;94(5):473-479. doi:10.1111/cge.13419
- 518 29. Hayashi M, Abe A, Murakami T, et al. Molecular analysis of the genes causing
- recessive demyelinating Charcot-Marie-Tooth disease in Japan. *J Hum Genet*.
- 520 2013;58(5):273-278. doi:10.1038/jhg.2013.15
- 521 30. DiVincenzo C, Elzinga CD, Medeiros AC, et al. The allelic spectrum of Charcot-
- Marie-Tooth disease in over 17,000 individuals with neuropathy. *Mol Genet Genomic*
- 523 *Med.* 2014;2(6):522-529. doi:10.1002/mgg3.106
- 31. Martikainen MH, Kytövuori L, Majamaa K. Novel mitofusin 2 splice-site mutation
- causes Charcot–Marie–Tooth disease type 2 with prominent sensory dysfunction.
- 526 Neuromuscular Disorders. 2014;24(4):360-364. doi:10.1016/J.NMD.2014.01.007
- 527 32. Piscosquito G, Saveri P, Magri S, et al. Screening for SH3TC2 gene mutations in a
- series of demyelinating recessive Charcot-Marie-Tooth disease (CMT4). J Peripher
- 529 Nerv Syst. 2016;21(3):142-149. doi:10.1111/jns.12175
- 530 33. Benedetti S, Previtali SC, Coviello S, et al. Analyzing histopathological features of
- rare Charcot-Marie-Tooth neuropathies to unravel their pathogenesis. *Arch Neurol*.
- 532 2010;67(12):1498-1505. doi:10.1001/archneurol.2010.303
- 533 34. Li MY, Yin M, Yang L, et al. A novel splicing mutation in 5'UTR of GJB1 causes X-
- 534 linked Charcot—Marie—tooth disease. *Mol Genet Genomic Med*. 2023;11(3):e2108.
- 535 doi:10.1002/MGG3.2108
- 536 35. Boso F, Taioli F, Cabrini I, Cavallaro T, Fabrizi GM. Aberrant Splicing in GJB1 and
- the Relevance of 5' UTR in CMTX1 Pathogenesis. *Brain Sci.* 2020;11(1):24.
- 538 doi:10.3390/brainsci11010024
- 539 36. Tomaselli PJPPJ, Rossor AM, Horga A, et al. Mutations in noncoding regions in GJB1
- are a major cause of X-linked CMT. *Neurology*. 2017;88(15):1445-1453.
- 541 doi:10.1212/WNL.000000000003819
- 542 37. Pravinbabu P, Holla V V, Phulpagar P, et al. A splice altering variant in NDRG1 gene
- causes Charcot-Marie-Tooth disease, type 4D. Neurol Sci. 2022;43(7):4463-4472.
- doi:10.1007/s10072-022-05893-4

- 545 38. Shchagina O, Orlova M, Murtazina A, Filatova A, Skoblov M, Dadali E. Evaluation of
- Pathogenicity and Causativity of Variants in the MPZ and SH3TC2 Genes in a Family
- Case of Hereditary Peripheral Neuropathy. *Int J Mol Sci.* 2023;24(12).
- 548 doi:10.3390/ijms24129786
- 549 39. Taioli F, Cabrini I, Cavallaro T, Simonati A, Testi S, Fabrizi GM. Déjerine-Sottas
- syndrome with a silent nucleotide change of myelin protein zero gene. *Journal of the*
- 551 *Peripheral Nervous System.* 2011;16(1):59-64. doi:10.1111/j.1529-8027.2011.00319.x
- 552 40. Sabet A, Li J, Ghandour K, et al. Skin biopsies demonstrate MPZ splicing
- abnormalities in Charcot-Marie-Tooth neuropathy 1B. *Neurology*. 2006;67(7):1141-
- 554 1146. doi:10.1212/01.wnl.0000238499.37764.b1
- 555 41. Lupo V. Characterising the phenotype and mode of inheritance of patients with
- inherited peripheral neuropathies carrying MME mutations. *J Med Genet*.
- 557 2018;55:814-823.
- 558 42. Masingue M, Perrot J, Carlier RY, Piguet-Lacroix G, Latour P, Stojkovic T. WES
- homozygosity mapping in a recessive form of Charcot-Marie-Tooth neuropathy
- reveals intronic GDAP1 variant leading to a premature stop codon. *Neurogenetics*.
- 561 2018;19(2):67-76. doi:10.1007/s10048-018-0539-7
- 562 43. Duyk GM, Kim SW, Myers RM, Cox DR. Exon trapping: a genetic screen to identify
- 563 candidate transcribed sequences in cloned mammalian genomic DNA. *Proceedings of*
- *the National Academy of Sciences*. 1990;87(22):8995-8999.
- 565 doi:10.1073/pnas.87.22.8995
- 566 44. Micale L, Morlino S, Schirizzi A, et al. Exon-Trapping Assay Improves Clinical
- 567 Interpretation of COL11A1 and COL11A2 Intronic Variants in Stickler Syndrome
- Type 2 and Otospondylomegaepiphyseal Dysplasia. *Genes (Basel)*. 2020;11(12):1513.
- doi:10.3390/genes11121513
- 570 45. Grosz BR, Tisch S, Tchan MC, et al. A novel synonymous KMT2B variant in a patient
- with dystonia causes aberrant splicing. *Mol Genet Genomic Med.* 2022;10(5).
- 572 doi:10.1002/MGG3.1923
- 573 46. Mutai H, Wasano K, Momozawa Y, et al. Variants encoding a restricted carboxy-
- terminal domain of SLC12A2 cause hereditary hearing loss in humans. *PLoS Genet*.
- 575 2020;16(4). doi:10.1371/journal.pgen.1008643
- 576 47. Knapp KM, Sullivan R, Murray J, et al. Linked-read genome sequencing identifies
- 577 biallelic pathogenic variants in DONSON as a novel cause of Meier-Gorlin syndrome.
- 578 J Med Genet. 2020;57(3):195-202. doi:10.1136/jmedgenet-2019-106396
- 579 48. Starokadomskyy P, Gemelli T, Rios JJ, et al. DNA polymerase-α regulates the
- 580 activation of type i interferons through cytosolic RNA:DNA synthesis. *Nat Immunol*.
- 581 2016;17(5):495-504. doi:10.1038/ni.3409
- 582 49. Varga L, Danis D, Skopkova M, et al. Novel EYA4 variant in Slovak family with late
- onset autosomal dominant hearing loss: A case report. *BMC Med Genet*. 2019;20(1).
- 584 doi:10.1186/s12881-019-0806-y

- 585 50. Legendre M, Rodriguez-Ballesteros M, Rossi M, et al. CHARGE syndrome: A
- recurrent hotspot of mutations in CHD7 IVS25 analyzed by bioinformatic tools and
- 587 minigene assays /631/208 /692/308 brief-communication. European Journal of Human
- 588 Genetics. 2018;26(2):287-292. doi:10.1038/s41431-017-0007-0
- 589 51. Abdulhay NJ, Fiorini C, Verboon JM, et al. Impaired human hematopoiesis due to a
- 590 cryptic intronic GATA1 splicing mutation. *Journal of Experimental Medicine*.
- 591 2019;216(5):1050-1060. doi:10.1084/jem.20181625
- 592 52. Kishore S, Khanna A, Stamm S. Rapid generation of splicing reporters with
- pSpliceExpress. Gene. 2008;427(1-2):104-110. doi:10.1016/j.gene.2008.09.021
- 594 53. Pedersen BS, Bhetariya PJ, Brown J, et al. Somalier: rapid relatedness estimation for
- cancer and germline studies using efficient genome sketches. *Genome Med*.
- 596 2020;12(1):62. doi:10.1186/s13073-020-00761-2
- 597 54. Pais LS, Snow H, Weisburd B, et al. seqr: A web-based analysis and collaboration tool
- for rare disease genomics. *Hum Mutat*. 2022;43(6):698-707.
- 599 doi:10.1002/HUMU.24366
- 55. Stark Z, Foulger RE, Williams E, et al. Scaling national and international improvement
- in virtual gene panel curation via a collaborative approach to discordance resolution.
- 602 Am J Hum Genet. 2021;108(9):1551-1557. doi:10.1016/j.ajhg.2021.06.020
- 56. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing
- from Primary Sequence with Deep Learning. *Cell*. 2019;176(3):535-548.e24.
- doi:10.1016/j.cell.2018.12.015
- 606 57. Payne A, Holmes N, Clarke T, Munro R, Debebe BJ, Loose M. Readfish enables
- targeted nanopore sequencing of gigabase-sized genomes. *Nat Biotechnol*.
- 608 2021;39(4):442-450. doi:10.1038/s41587-020-00746-x
- 58. Stevanovski I, Chintalaphani SR, Gamaarachchi H, et al. Comprehensive genetic
- 610 diagnosis of tandem repeat expansion disorders with programmable targeted nanopore
- sequencing. *Sci Adv.* 2022;8(9). doi:10.1126/SCIADV.ABM5386
- 612 59. Gamaarachchi H, Samarakoon H, Jenner SP, et al. Fast nanopore sequencing data
- analysis with SLOW5. *Nat Biotechnol*. 2022;40(7):1026-1029. doi:10.1038/s41587-
- 614 021-01147-4
- 615 60. Samarakoon H, Ferguson JM, Jenner SP, et al. Flexible and efficient handling of
- nanopore sequencing signal data with slow5tools. Genome Biol. 2023;24(1):69.
- doi:10.1186/s13059-023-02910-3
- 61. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics*.
- 619 2018;34(18):3094-3100. doi:10.1093/bioinformatics/bty191
- 620 62. Zheng Z, Li S, Su J, Leung AWS, Lam TW, Luo R. Symphonizing pileup and full-
- 621 alignment for deep learning-based long-read variant calling. *Nat Comput Sci*.
- 622 2022;2(12):797-803. doi:10.1038/s43588-022-00387-x

- 623 63. Martin M, Patterson M, Garg S, et al. WhatsHap: fast and accurate read-based phasing.
  624 Published online 2016. doi:10.1101/085050
- 625 64. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative Genomics Viewer. *Nat Biotechnol.* 2011;29(1):24. doi:10.1038/NBT.1754
- 627 65. Zeng Z, Bromberg Y. Predicting Functional Effects of Synonymous Variants: A
   628 Systematic Review and Perspectives. *Front Genet*. 2019;0:914.
- doi:10.3389/FGENE.2019.00914
- 630 66. Kishore Jaganathan A, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting
- Splicing from Primary Sequence with Deep Learning In Brief A deep neural network
- precisely models mRNA splicing from a genomic sequence and accurately predicts
- noncoding cryptic splice mutations in patients with rare genetic diseases. Predicting
- Splicing from Primary Sequence with Deep Learning. *Cell*. 2018;176:535-548.
- 635 doi:10.1016/j.cell.2018.12.015
- 636 67. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic
- variation. *Nucleic Acids Res.* 2001;29(1):308-311. Accessed March 5, 2019.
- http://www.ncbi.nlm.nih.gov/pubmed/11125122
- 639 68. Chen S, Francioli LC, Goodrich JK, et al. A genomic mutational constraint map using variation in 76,156 human genomes. *Nature*. 2024;625(7993):92-100.
- doi:10.1038/s41586-023-06045-0
- 642 69. All of Us Research Program Investigators, Denny JC, Rutter JL, et al. The "All of Us" Research Program. *N Engl J Med*. 2019;381(7):668-676. doi:10.1056/NEJMsr1809937
- 70. Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from
- the NHLBI TOPMed Program. *Nature*. 2021;590(7845):290-299. doi:10.1038/s41586-
- 646 021-03205-y
- 71. Kent WJ. <tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool. *Genome Res.* 2002;12(4):656-664. doi:10.1101/gr.229202
- 649 72. Castle JC. SNPs occur in regions with less genomic sequence conservation. *PLoS One*.
- 650 2011;6(6):e20660. doi:10.1371/journal.pone.0020660
- 651 73. Boisson M, Arrondel C, Cagnard N, et al. A wave of deep intronic mutations in X-
- linked Alport syndrome. *Kidney Int.* 2023;104(2):367-377.
- doi:10.1016/j.kint.2023.05.006
- 654 74. Qian X, Wang J, Wang M, et al. Identification of Deep-Intronic Splice Mutations in a
- Large Cohort of Patients With Inherited Retinal Diseases. *Front Genet*.
- 656 2021;12:647400. doi:10.3389/fgene.2021.647400
- 657 75. Di Scipio M, Tavares E, Deshmukh S, et al. Phenotype Driven Analysis of Whole
- 658 Genome Sequencing Identifies Deep Intronic Variants that Cause Retinal Dystrophies
- by Aberrant Exonization. *Invest Ophthalmol Vis Sci.* 2020;61(10):36.
- doi:10.1167/iovs.61.10.36

- 76. Xie Z, Sun C, Liu Y, et al. Practical approach to the genetic diagnosis of unsolved
- dystrophinopathies: a stepwise strategy in the genomic era. *J Med Genet*.
- 2021;58(11):743-751. doi:10.1136/jmedgenet-2020-107113
- 664 77. Zaum AK, Stüve B, Gehrig A, et al. Deep intronic variants introduce DMD
- pseudoexon in patient with muscular dystrophy. Neuromuscul Disord. 2017;27(7):631-
- 666 634. doi:10.1016/j.nmd.2017.04.003
- 667 78. Anna A, Monika G. Splicing mutations in human genetic disorders: examples,
- detection, and confirmation. J Appl Genet. 2018;59(3):253-268. doi:10.1007/s13353-
- 669 018-0444-7
- 670 79. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of
- sequence variants: A joint consensus recommendation of the American College of
- Medical Genetics and Genomics and the Association for Molecular Pathology.
- 673 Genetics in Medicine. 2015;17(5):405-424. doi:10.1038/gim.2015.30
- 674 80. Depondt C, Donatello S, Rai M, et al. MME mutation in dominant spinocerebellar
- ataxia with neuropathy (SCA43). Neurol Genet. 2016;2(5):e94.
- doi:10.1212/NXG.0000000000000094
- 81. Kim J, Woo S, de Gusmao CM, et al. A framework for individualized splice-switching
- oligonucleotide therapy. *Nature*. 2023;619(7971):828-836. doi:10.1038/s41586-023-
- 679 06277-0
- 680 82. Chen S, Heendeniya SN, Le BT, et al. Splice-Modulating Antisense Oligonucleotides
- as Therapeutics for Inherited Metabolic Diseases. *BioDrugs*. 2024;38(2):177-203.
- doi:10.1007/s40259-024-00644-7
- 83. Santos JI, Gonçalves M, Matos L, et al. Splicing Modulation as a Promising
- Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses
- Example. Life. 2022;12(5):608. doi:10.3390/life12050608
- 686 84. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of
- Duchenne muscular dystrophy. *Ann Neurol*. 2013;74(5):637-647.
- 688 doi:10.1002/ana.23982
- 689 85. Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen
- in patients with Duchenne muscular dystrophy. *Neurology*. 2020;94(21):e2270-e2282.
- doi:10.1212/WNL.0000000000009233
- 692 86. Heo YA. Golodirsen: First Approval. *Drugs*. 2020;80(3):329-333.
- 693 doi:10.1007/s40265-020-01267-2
- 694 87. Clemens PR, Rao VK, Connolly AM, et al. Safety, Tolerability, and Efficacy of
- 695 Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53
- 696 Skipping: A Phase 2 Randomized Clinical Trial. *JAMA Neurol*. 2020;77(8):982-991.
- 697 doi:10.1001/jamaneurol.2020.1264
- 698 88. Shirley M. Casimersen: First Approval. *Drugs*. 2021;81(7):875-879.
- doi:10.1007/s40265-021-01512-2

- 700 89. Wurster CD, Winter B, Wollinsky K, et al. Intrathecal administration of nusinersen in
- adolescent and adult SMA type 2 and 3 patients. *J Neurol*. 2019;266(1):183-194.
- 702 doi:10.1007/s00415-018-9124-0
- 703 90. Osredkar D, Jílková M, Butenko T, et al. Children and young adults with spinal
- muscular atrophy treated with nusinersen. Eur J Paediatr Neurol. 2021;30:1-8.
- 705 doi:10.1016/j.ejpn.2020.11.004
- 706 91. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-
- 707 Onset Spinal Muscular Atrophy. *N Engl J Med*. 2018;378(7):625-635.
- 708 doi:10.1056/NEJMoa1710504
- 709 92. Bianchi L, Sframeli M, Vantaggiato L, et al. Nusinersen Modulates Proteomics
- Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients. *Int J Mol*
- 711 *Sci.* 2021;22(9). doi:10.3390/ijms22094329
- 712 93. Kim J, Woo S, de Gusmao CM, et al. A framework for individualized splice-switching
- 713 oligonucleotide therapy. *Nature*. 2023;619(7971):828-836. doi:10.1038/s41586-023-
- 714 06277-0
- 715 94. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide
- Therapy for a Rare Genetic Disease. *N Engl J Med*. 2019;381(17):1644-1652.
- 717 doi:10.1056/NEJMoa1813279
- 718 95. Yamada M, Maeta K, Suzuki H, et al. Successful skipping of abnormal pseudoexon by
- antisense oligonucleotides in vitro for a patient with beta-propeller protein-associated
- 720 neurodegeneration. *Sci Rep.* 2024;14(1):6506. doi:10.1038/s41598-024-56704-z
- 721 96. Aguti S, Bolduc V, Ala P, et al. Exon-Skipping Oligonucleotides Restore Functional
- 722 Collagen VI by Correcting a Common COL6A1 Mutation in Ullrich CMD. *Mol Ther*
- 723 Nucleic Acids. 2020;21:205-216. doi:10.1016/J.OMTN.2020.05.029
- 724 97. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide
- 725 Therapy for a Rare Genetic Disease. *N Engl J Med*. 2019;381(17):1644-1652.
- 726 doi:10.1056/NEJMOA1813279
- 727 98. Dominov JA, Uyan Ö, McKenna Yasek D, et al. Correction of pseudoexon splicing
- 728 caused by a novel intronic dysferlin mutation. Ann Clin Transl Neurol. 2019;6(4):642-
- 729 654. doi:10.1002/acn3.738

- 730 99. Martínez-Pizarro A, Leal F, Holm LL, et al. Antisense Oligonucleotide Rescue of
- 731 Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin
- 732 Synthase Gene. Nucleic Acid Ther. 2022;32(5):378-390. doi:10.1089/nat.2021.0066

Table 1. Phenotypic characterization of individuals with recessive CMT *MME* variants reported in this manuscript. Abbreviations- AFO: Ankle foot orthoses; CMTNS: Charcot-Marie-Tooth Neuropathy Score; UL/LL: Upper Limb/Lower Limb

Family #	Family 1	Family 2			
Individual	V:1	V:3	V:4	V:6	II:1
Sex	M	F	M	M	F
Onset	Fourth decade	Childhood	Childhood	Childhood	Early-adult
Age at evaluation	60-65	65-70	65-70	65-70	50-55
(years)					
Presenting symptom	Gait unsteadiness	Difficulty running	Difficulty sitting on crossed	Difficulty running,	Bilateral leg weakness
			legs during childhood	multiple ankle sprains	and sensory disturbance
Atrophy UL/LL	Yes/yes	Yes/yes	Yes/yes	Yes/yes	No/Yes
					(left calf only)
Foot deformity	None	Pes cavus/hammer toes	-	Pes cavus	Pes cavus
Tone UL/LL	Normal/reduced	Normal/normal	Normal, increased		Normal/normal
Shoulder abduction	5	5	3	5	4
Elbow flexion	4	5	3	4	5
Elbow extension	4	5	3	4	5

Finger abduction	2	4	3	1	4
Hip flexion	4	3	3	3	4
Knee extension	4	3	3	4	4
Knee flexion	4	3	3	4	4
Ankle dorsiflexion	0	0	3	1	3
Ankle plantarflexion	0	0	3	0	4
Deep tendon	Absent/absent	Absent ankle	Hyperreflexia knee, absent	Absent/absent	Normal/ reduced ankle
reflexes UL/LL			ankle		reflexes
Plantars	Absent	-	Absent	Flexor	Flexor
Proprioception	Normal/reduced to	-	-	Normal/reduced to the	Normal/reduced to ankle
UL/LL	the MTP			ankle	
Vibration UL/LL	Normal/reduced to	Absent in toes	-	Reduced to	Reduced to mid-shin
	ankle			wrist/reduced to knees	
Pinprick UL/LL	Normal/reduced to	Normal/reduced to the	Reduced to elbows/reduced	Reduced to PIP	Reduced to mid-shin
	ankle	mid shin	to knees	joint/reduced to knees	Reduced dorsum hand
Temperature	Normal/reduced to	-	-	Reduced to	Reduced to mid-shin
sensation UL/LL	ankle			wrist/reduced to above	

				knee	
Other	Cough	GORD and cough	Corticospinal tract signs	Nil	Fatty infiltration on left
symptoms/signs					gastrocnemius
Gait	High steppage/ataxic	High steppage/ataxic	Steppage gait	High steppage/ataxic	High steppage
Romberg's sign	Positive	Positive		Positive	Mild sway
Mobility aids	AFO, walking stick and mobility scooter	AFO, walker	AFO, walker, mobility scooter	Wheelchair	AFO, elbow crutch
CMTNS (version 2)	31	-	28/36	36	15

Table 2. Nerve conduction study (NCS) findings of individuals with recessive CMT *MME* variants reported in this manuscript. Abbreviations: APB: abductor pollicis brevis; ADM: abductor digiti minimi; EDB: extensor hallucis brevis; FHB: flexor hallus brevis; CMAP: compound motor action potential; CV: conduction velocity; NR: no response; SNAP: sensory nerve action potential; R: right, L:left.

Family #	Family 1		Family 2	
Individual	V:1	V:6	II:1	
Age at NCS (years)	60-65	65-70	55-60	
Median nerve (digit II) [ortho	odromic(R)]		I	
SNAP (uV)	NR	NR	6.6	
CV (m/s)	NR	NR	50	
Ulnar nerve (digit V) [orthod	dromic(R)]			
SNAP (uV)	NR	1	4.9	
CV (m/s)	NR	40.2	51	
Sural nerve [orthodromic(R)	]			
SNAP (uV)	NR	NR	NR	
CV (m/s)	NR	NR	NR	
Sural nerve [orthodromic(L)]	]			

SNAP (uV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Median nerve (APB) (R)	I	<u> </u>	
CMAP (mV)	NR	NR	4.8
CV (m/s)	NR	NR	41
Ulnar nerve (ADM) (R)			
CMAP (mV)	2	0.6	6.6
CV (m/s)	44.4	44.7	52 (wrist-below elbow)
			57 (wrist-above elbow)
Peroneal nerve (EDB) (R)			
CMAP (mV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Tibial nerve (FHB) (L)			
CMAP (mV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Needle EMG	Absent voluntary units in the right tibilias anterior and medial gastrocnemius muscles, as well as	Absent recruitment of motor units in the right tibialis anterior, medical gastrocnemius, first dorsal interesseous and vastus lateralis	Reduced recruitment of motor units in the right tibialis interior and right vastus medialis muscles. Discrete
	denervation-reinnervation changes in	interosseous and vastus lateralis	recruitment of muscle fibres in the

the right vastus lateralis muscle.	muscles. Denervation-reinnervation right gastrocnemius muscle.
	changes were evident in the right
	deltoid, biceps brachii and triceps
	brachii muscles.



